Claim 17, line 1, after "disease" insert --in a patient--.

Please add the following new claims:

~~18~~ 19. The method of Claim 17, wherein said disease is a malignancy associated with a tumor, and wherein said cells are transformed with a DNA sequence or an RNA sequence encoding an intracellular, secreted, or cell surface molecule which is (1) exogenous to said patient and which is (2a) immunogenic to said patient, (2b) induces rejection, regression, or both of said tumor, or (2c) toxic to the cells of said tumor.

~~19~~ 20. The method of Claim 21, wherein said molecule is immunogenic to said patient.

~~20~~ 21. The method of Claim 21, wherein said molecule induces rejection, regression, or both, of said tumor.

~~21~~ 22. The method of Claim 23, wherein said molecule is a growth stimulant or inhibitor.

~~22~~ 23. The method of Claim 23, wherein said molecule is an inducer of cellular differentiation.

~~23~~ 24. The method of Claim 21, wherein said molecule is toxic to the cells of said tumor.

~~24~~ 25. The method of Claim 21, wherein said DNA or RNA sequence is obtained from a species which is the same as said patient.

~~25~~ 26. The method of Claim 21, wherein said DNA or RNA sequence is obtained from a species different than the species of said patient.

26. ~~29.~~ The method of Claim 21, wherein said DNA or RNA sequence is administered locally to said patient in a viral vector.

27. ~~30.~~ The method of Claim 21, wherein said DNA or RNA sequence is administered locally to said patient as a DNA or RNA/liposome complex.

28. ~~31.~~ The method of Claim 21, wherein said DNA or RNA sequence is administered locally to said patient <u>via</u> a cell line.

29. ~~32.~~ The method of Claim 21, wherein said DNA or RNA sequence is administered to said patient systemically as a chemical formulation containing said DNA or RNA sequence coupled to a carrier ~~molecule~~ which facilitates delivery of said sequence to target cells in said patient.

30. ~~33.~~ The method of Claim 21, wherein said DNA or RNA sequence is one member selected from the group consisting of Class I histocompatibility genes, Class II histocompatibility genes, bacterial genes encoding peptides having immunostimulant properties, genes encoding viral glycoproteins having immunostimulant properties, genes encoding minor histocompatibility antigens, genes encoding lysozymes or bovine serum albumin, and oncogenes.

31. ~~34.~~ The method of Claim 21, wherein said DNA or RNA sequence is one member selected from the group consisting of DNA or RNA sequences encoding interleukin-1, 2, 3, 4, 6 or 8, TNF-α or β, TGF-β (1, 2 or 3), soluble growth factors,